PCYT1A

Across TCGA pan-cancer cohorts, PCYT1A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCYT1A data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PCYT1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCYT1A expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where PCYT1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.595	0.926	<.001	43	view →
UCEC	OS	Tertile	II,III,IV	0.434	1.000	.008	20	view →
LSCC	OS	Median	III,IV	0.451	0.840	.015	9	view →
LUAD	OS	Tertile	II,III,IV	0.911	0.368	.005	8	view →
PDAC	DFS	Median	III,IV	0.188	0.529	.007	8	view →
HNSC	DFS	Tertile	All	1.000	0.939	.021	6	view →
GBM	DFS	Median	All	0.621	0.854	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCYT1A–CCRCC (DFS)

Open the CCRCC breakdown →